



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
(Incorporated in Malaysia)  
**Quarterly Report On Results For The Period Ended 30 September 2007**  
**NOTES TO INTERIM FINANCIAL REPORT**

**A1 Accounting Policies and Method of Computation**

The interim financial report is unaudited and has been prepared in accordance with the applicable disclosure provisions of Listing Requirements of Bursa Malaysia Securities Berhad including compliance with Financial Reporting Standard (FRS) 134 <sup>2004</sup>, *Interim Financial Reporting*, issued by the Malaysian Accounting Standards Board (MASB)

The preparation of an interim financial report in conformity with FRS 134 <sup>2004</sup>, *Interim Financial Reporting* requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from those estimates.

**A2 Changes in accounting policies**

The significant accounting policies adopted by the Group in preparing the interim financial statement, are consistent with those of the audited financial statements for the year ended 31 December 2006 except for the adoption of the new / revised FRSs that are effective for accounting period beginning on or after 1 January 2007.

**A3 Audit Report**

The audited report of the Company's preceding annual financial statements was not qualified.

**A4 Seasonal or Cyclical Factors**

The business operations of the Group are not materially affected by any seasonal or cyclical factors.

**A5 Unusual items due to their nature, size or incidence**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows during the current quarter.

**A6 Changes in Estimates**

There were no changes in estimates of amounts reported in prior financial years that have a material effect in the current quarter.

**A7 Debts and Equity Securities**

There are no issuance, cancellations, repurchases, resale and repayments of debts and equity securities for the current quarter to date other than issuance of 28,500 new ordinary shares of RM0.50 each at an issue price of RM2.32 pursuant to the Employees' Share Option Scheme (ESOS) as follows:

Month	No of Shares Issued	Cash Proceed
Sept 07	28,500	66,120
TOTAL	28,500	66,120

**A8 Dividend Paid**

During the current quarter, no interim dividend was paid (2006: An interim dividend of 14% (7.0 sen) per share less 28% income tax amounting to approximately RM6.99 million has been paid on 22 September 2006).

Subsequent to current quarter, an interim dividend of 28% (14 sen) per share less 27% income tax amounting to approximately RM14.19 million in respect of financial year ending 31 December 2007 was paid on 18 October 2007.

**A9 Segment Information**

There is no segmental reporting as the Group's activities are principally in pharmaceutical industry; and its operations are carried out solely in Malaysia.

**A10 Property, Plant and Equipment**

The valuation of property, plant and equipment used in the condensed financial statements have been brought forward without amendment from the previous annual financial statements.

**A11 Post Balance Sheet Events**

There are no material events after the period end up to 19 November 2007 (latest practicable date which is not earlier than 7 days from the date of issuance of this quarterly report) that have not been reflected in the financial statements for the financial period ended 30 September 2007.

**A12 Changes in the Composition of the Group**

There were no changes in the composition of the Group during the current quarter.

**A13 Contingent Liabilities**

Contingent liabilities as at 19 November 2007 (latest practicable date which is not earlier than 7 days from the date of issuance of this quarterly report) is as follows:-

	<u>RM' 000</u>
Guarantees for banking facilities granted to its subsidiary	<u>22,680</u>

**A14 Related Parties Transactions**

Significant related parties transactions of the Group for the period ended 30 September 2007 are as follows:-

	<u>RM ' 000</u>
a) With CCM Pharmaceuticals (S) Pte Ltd, a wholly owned subsidiary of CCM International Sdn Bhd which in turn is a wholly-owned subsidiary of CCM Marketing Sdn Bhd.	
-Sales of goods	<u>1,780</u>
b) With CCM Chemicals Sdn Bhd, a company in which Chemical Company of Malaysia Berhad has a direct interest of 80.0%	
-Purchase of goods	<u>214</u>
c) With CCM Marketing Sdn Bhd, a company in which Chemical Company of Malaysia Berhad has a direct interest of 100.0%	
-Sales of goods	<u>356</u>
d) With CCM Pharmaceuticals Sdn Bhd, a company in which Chemical Company of Malaysia Berhad has a direct interest of 100.0%	
-Purchase of goods	<u>1,330</u>

**ADDITIONAL INFORMATION REQUIRED BY BURSA SECURITIES LISTING REQUIREMENTS**
**B1 Review of Performance**

The Group recorded a revenue and profit before tax (PBT) of RM27.68 million and RM9.82 million respectively for current quarter ended 30 September 2007 as compared to RM26.22 million and RM9.69 million for the corresponding quarter last year. The growth in revenue and PBT is mainly attributable to the Group's continuous effort to enhance products mix that potentially generates higher returns.

**B2 Comparison with the Preceding Quarter's Results**

	Qtr 3 2007 (30/9/07) RM'000	Qtr 2 2007 (30/6/07) RM'000	Variance	
			RM'000	%
Revenue	27,678	27,699	(21)	(0.08)
Profit before tax	9,823	10,468	(645)	(6.16)
Profit after tax	7,548	7,559	(11)	(0.15)

The Group recorded revenue and profit after tax (PAT) of RM27.68 million and RM7.55 million respectively for the current financial quarter as compared to RM27.70 million and RM7.56 million respectively for the preceding financial quarter. The marginal decrease in revenue was mainly due to slower sales in government hospitals and tenders.

**B3 Prospects for the Remainder of Current Financial Year**

The Board expects the Group to achieve satisfactory results for the remaining period of current financial year under normal business environment.

**B4 Profit Forecast**

No commentary is made on any variance between actual profit from forecast profit as it does not apply to the Group.

**B5 Taxation**

Details of taxation are as follows :-

	Current Year	Current Year
	Quarter	To Date
	30/9/07	30/9/07
	RM'000	RM'000
Based on results for the quarter/year	2,220	7,572
Transfer to/(from) deferred tax	55	545
	<u>2,275</u>	<u>8,117</u>

The Group's effective tax rate is lower than the statutory tax rate mainly due to the utilisation of reinvestment allowances in a subsidiary.

**B6 Unquoted Investments and Properties**

There was no disposal of unquoted investment and/or properties during the current financial quarter.

**B7 Quoted Investments**

There was no purchase or disposal of quoted securities during the current financial quarter.

**B8 Status of corporate proposals.**

There were no new corporate proposal announced as at the date of the report.

**B9 Borrowings and Debt Securities**

The Group does not have any borrowings as at the end of the current financial quarter.

**B10 Off Balance Sheet Financial Instruments**

The Group does not have any off balance sheet financial instruments as at the date of issue of this quarterly report.

**B11 Material litigation**

There was no material litigation up to 19 November 2007 (latest practicable date which is not earlier than 7 days from the date of issuance of this quarterly report).

**B12 Dividend**

For the current financial period ended 30 September 2007, the Board of Directors is recommending a special interim dividend of 68% (34sen) per share less 27% income tax based on paid up capital of approximately 139million shares at par value of RM0.50 each (2006:nil). This is in line with the increase in profit after tax and also changes in tax legislation from imputation system to single tier system. The book closure date in respect of the special interim dividend is on 12 December 2007 and the dividend will be paid on 24 December 2007.

**B13 Earnings per Share**

	Current year quarter 30/9/07	Current year to date 30/9/07
a) <b>Basic EPS</b>		
Net profit (RM'000)	7,548	23,041
Weighted average number of ordinary shares in issue ('000)		
- Balance b/f	138,775	138,775
-Weighted average number of shares arising from options exercised during the period	1	1
	138,776	138,776
Basic EPS (sen)	5.44	16.60
b) <b>Dilutive EPS</b>		
Adjusted weighted average number of ordinary shares in issue ('000)		
-In issue during the period	138,776	138,776
-Dilutive impact of unexercised share options	19	19
	138,795	138,795
Dilutive EPS (sen)	5.44	16.60

**B14 Authorisation for issue**

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the directors on 26 November 2007.

By Order of the Board

Noor Azwah binti Samsudin  
Rosnah binti Mahat  
Secretaries  
Kuala Lumpur  
26 November 2007